Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of TS-172 with Triazolam and Itraconazole in Healthy Men
NCT06837142Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TS-172 in hyperphosphatemia (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Maximum plasma concentration of unchanged form of triazolam, Area under the concentration-time curve of unchanged form of triazolam and 2 more. Started Mar 2025; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06837142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837142.